Biotech ETFs have done quite done well this year as many pharma and biotech companies are working on coronavirus vaccines, therapeutics and testing. Some of these therapeutics, including Gilead’s ( GILD) antiviral drug remdesivir and Regeneron’s ( REGN) experimental antibody treatment were given to President Trump.
Genomics stocks and ETFs have been in focus since Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in developing the Crispr technology. The revolutionary gene editing technology works like powerful molecular scissors to cut and edit genes in any living creature and has limitless applications.
The ARK Genomic Revolution ETF (
ARKG) is an actively managed ETF that has surged over 120% this year. Invitae Corporation ( NVTA) and CRISPR Therapeutics ( CRSP) are its top holdings.
To learn more about ARKG, the iShares Genomics Immunology and Healthcare ETF (
IDNA) and the Global X Genomics & Biotechnology ETF ( GNOM), please watch the short video above. Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks
Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Invitae Corporation (NVTA): Free Stock Analysis Report CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report ARK Genomic Revolution ETF (ARKG): ETF Research Reports Global X Genomics Biotechnology ETF (GNOM): ETF Research Reports iShares Genomics Immunology and Healthcare ETF (IDNA): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.